147 related articles for article (PubMed ID: 32905663)
21. Hypoxia inducible factor 1α-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer.
Ji F; Wang Y; Qiu L; Li S; Zhu J; Liang Z; Wan Y; Di W
Int J Oncol; 2013 May; 42(5):1578-88. PubMed ID: 23545606
[TBL] [Abstract][Full Text] [Related]
22. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
23. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
24. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
26. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
27. MiRNA-451 Inhibits Glioma Cell Proliferation and Invasion Through the mTOR/HIF-1α/VEGF Signaling Pathway by Targeting CAB39.
Nan Y; Guo H; Guo L; Wang L; Ren B; Yu K; Huang Q; Zhong Y
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):156-166. PubMed ID: 30180756
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
29. Cinobufagin suppresses colorectal cancer angiogenesis by disrupting the endothelial mammalian target of rapamycin/hypoxia-inducible factor 1α axis.
Li X; Chen C; Dai Y; Huang C; Han Q; Jing L; Ma Y; Xu Y; Liu Y; Zhao L; Wang J; Sun X; Yao X
Cancer Sci; 2019 May; 110(5):1724-1734. PubMed ID: 30839155
[TBL] [Abstract][Full Text] [Related]
30. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression.
Park MS; Kim BR; Dong SM; Lee SH; Kim DY; Rho SB
Oncotarget; 2014 Jul; 5(13):4935-44. PubMed ID: 24952732
[TBL] [Abstract][Full Text] [Related]
31. Jianpi Jiedu decoction, a traditional Chinese medicine formula, inhibits tumorigenesis, metastasis, and angiogenesis through the mTOR/HIF-1α/VEGF pathway.
Peng W; Zhang S; Zhang Z; Xu P; Mao D; Huang S; Chen B; Zhang C; Zhang S
J Ethnopharmacol; 2018 Oct; 224():140-148. PubMed ID: 29852266
[TBL] [Abstract][Full Text] [Related]
32. Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1α via the mTOR/p70S6K/4E-BP1 and MAPK pathways.
Mi C; Ma J; Wang KS; Zuo HX; Wang Z; Li MY; Piao LX; Xu GH; Li X; Quan ZS; Jin X
J Ethnopharmacol; 2017 May; 203():27-38. PubMed ID: 28341244
[TBL] [Abstract][Full Text] [Related]
33. Dictamnine promotes apoptosis and inhibits epithelial-mesenchymal transition, migration, invasion and proliferation by downregulating the HIF-1α and Slug signaling pathways.
Wang JY; Wang Z; Li MY; Zhang Z; Mi C; Zuo HX; Xing Y; Wu YL; Lian LH; Xu GH; Piao LX; Ma J; Jin X
Chem Biol Interact; 2018 Dec; 296():134-144. PubMed ID: 30266538
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer.
Gomez-Roman N; Sahasrabudhe NM; McGregor F; Chalmers AJ; Cassidy J; Plumb J
Oncotarget; 2016 Apr; 7(16):22650-64. PubMed ID: 26967059
[TBL] [Abstract][Full Text] [Related]
35. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
36. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
37. IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells.
Xu S; Yu C; Ma X; Li Y; Shen Y; Chen Y; Huang S; Zhang T; Deng W; Wang Y
Eur J Pharmacol; 2021 Mar; 894():173817. PubMed ID: 33345849
[TBL] [Abstract][Full Text] [Related]
38. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
39. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
40. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.
Ao Q; Su W; Guo S; Cai L; Huang L
Sci Rep; 2015 Nov; 5():16396. PubMed ID: 26548925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
